FDA Panel Shifts with Peptide Industry Ties | Global News

The FDA is set to revisit controversial peptide drugs next month, but this time the panel includes doctors and pharmacists directly profiting from the industry—unlike past panels dominated by academic experts. These peptides, often sold online or in wellness clinics for muscle gain, anti-aging, and recovery, skirt FDA rules by labeling them “for research use only.” Compounding pharmacies play a key role, creating custom versions of unapproved drugs. Past panels rejected these substances as too risky, but now voices from clinics, social media influencers, and even a pharmacist whose mother is a Congresswoman are on the table. Amid criticism from Health Secretary Robert F. Kennedy Jr. and his allies over conflicts of interest, the inclusion of industry insiders raises serious questions about regulatory integrity and public health priorities. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e8beed460650107a